CNBC Top NewsCodex · 实盘不做把握 8/10
北京时间·🕒 发布 08-03 19:53:47时区推断·⟳ 抓取 08-03 19:56:15·⚡ 决策 08-04 14:51:19 +18h55m·84.3 天前
Curium拟以每股102.50美元现金加最高12美元CVR收购Lantheus
Lantheus股东可获得102.50美元现金加最高12美元CVR，总对价最高114.50美元/股，对上次收盘价99.64美元溢价约14.9%。
📄 原文CNBC Top News↗ 原文
Curium strikes up to $8 billion deal for radiopharma peer Lantheus
Thomas Fuller | Lightrocket | Getty Images Curium has agreed to buy radiopharmaceutical company Lantheus Holdings in a…
不做 Lantheus Holdings（LNTH.US）
同一具体催化已在已处理事件库中由IR、SEC、Reuters、Bloomberg等来源处理，当前CNBC转述不再重复推卡。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 high · price-in 风险 high ↗
关键理由
- Lantheus股东可获得102.50美元现金加最高12美元CVR，总对价最高114.50美元/股，对上次收盘价99.64美元溢价约14.9%。
主要风险
- 同一具体收购催化已在近72小时已处理事件库中多次出现，当前CNBC转述不应重复推卡。
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- normalize_ticker · 结果未知
原文全文
展开原文 · 736 字
Thomas Fuller | Lightrocket | Getty Images
Curium has agreed to buy radiopharmaceutical company Lantheus Holdings in a deal worth up to $8 billion, the companies said on Monday.
Under the agreement, Lantheus shareholders will get $102.50 per share in cash when the deal closes, plus rights to receive up to $12 more per share if certain sales targets are met by 2030.
The total consideration of up to $114.50 per share represents a premium of about 14.9% to Lantheus' last closing price of $99.64.
"We believe this transaction is the ultimate validation of what the Lantheus team has built over seven decades of innovation in radiopharmaceuticals," said Lantheus CEO Mary Anne Heino.
Shares of Lantheus were halted in premarket trading.
Curium has agreed to buy radiopharmaceutical company Lantheus Holdings in a deal worth up to $8 billion, the companies said on Monday.
Under the agreement, Lantheus shareholders will get $102.50 per share in cash when the deal closes, plus rights to receive up to $12 more per share if certain sales targets are met by 2030.
The total consideration of up to $114.50 per share represents a premium of about 14.9% to Lantheus' last closing price of $99.64.
"We believe this transaction is the ultimate validation of what the Lantheus team has built over seven decades of innovation in radiopharmaceuticals," said Lantheus CEO Mary Anne Heino.
Shares of Lantheus were halted in premarket trading.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。